Therapeutic induction of effector CD4 T cell responses against EBV antigen to fight malignancies demonstrate promise in animal models; effective killing of virus-induced tumor cells following treatment with a CD137 agonist was seen in CD8 T cell-deficient mice (150). The gene discussed is TNFRSF9; the disease is neoplasm.